Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
ID: 351179Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $150K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351179

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-013.html
Timeline
    Description

    The National Institutes of Health (NIH), through its National Cancer Institute (NCI), is offering a funding opportunity aimed at encouraging revision applications for currently funded NCI U01 research projects to incorporate novel technologies developed under the Innovative Molecular Analysis Technologies (IMAT) program. Applicants are expected to enhance their original research aims and demonstrate independent validation of these technologies to accelerate cancer research and promote interdisciplinary collaboration. This initiative is critical for advancing innovative tools and methods in oncology, with approximately three awards available, totaling $600,000, and individual budgets capped at $150,000 per year for a maximum of two years. Interested applicants should note that the application period opens on March 1, 2024, with a submission deadline of October 2, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-013-Full-Announcement.html
    RFA-CA-24-013.html
    The National Institutes of Health (NIH), through its National Cancer Institute (NCI), is issuing a Notice of Funding Opportunity (NOFO) aimed at encouraging revisions to currently funded NCI U01 research projects. This initiative is focused on incorporating novel technologies developed under the Innovative Molecular Analysis Technologies (IMAT) program to further cancer research. Proposed projects should enhance the original aims and demonstrate independent validation of these technologies for broader scientific utility. Key dates include an application opening on March 1, 2024, with a deadline of October 2, 2024. Approximately three awards, totaling $600,000, will be granted, with budgets capped at $150,000 for direct costs per year over a maximum of two years. All applicants must adhere to strict guidelines regarding submission and eligibility, ensuring compliance with the NIH Grants Policy and submission requirements via Grants.gov or the NIH ASSIST system. Overall, this funding opportunity emphasizes interdisciplinary collaboration, technology advancement in cancer studies, and rigorous data management processes, reflecting NIH's commitment to fostering innovation and scientific discovery in oncology research.
    Similar Opportunities
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)." This initiative invites revision applications from currently funded NCI R01 research projects, encouraging applicants to enhance their original research by integrating innovative technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program. The goal is to foster interdisciplinary collaboration and accelerate scientific discovery in cancer research. Interested applicants can apply for grants of up to $150,000 annually for a maximum of two years, with applications accepted starting March 1, 2024, and a submission deadline of October 1, 2024. For further details, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-012.html.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for revision applications aimed at incorporating novel technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program to accelerate cancer research. This initiative encourages currently funded NCI P50 specialized centers to expand upon their original research questions by integrating innovative tools and methods, thereby promoting interdisciplinary collaboration and enhancing the rigor of ongoing studies. With a funding ceiling of $150,000 per year and a total of approximately $600,000 anticipated to support three awards for fiscal year 2025, eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and foreign entities. Interested parties should submit their applications by October 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research," aimed at enhancing cancer research through innovative technologies. This initiative encourages currently funded NCI P30 Cancer Center Support Grants (CCSG) recipients to expand their research by integrating new technical approaches developed through the NCI's Innovative Molecular Analysis Technologies (IMAT) program. The program is designed to foster interdisciplinary collaboration and promote independent validation of emerging technologies, thereby accelerating scientific discovery in cancer research. Interested applicants can apply for up to $150,000 per year, with a total funding pool of approximately $600,000 available for up to three awards. Applications are due by 5 PM local time on October 2, 2024, and further inquiries can be directed to grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-015.html.
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" initiative, which is part of the Innovative Molecular Analysis Technologies (IMAT) Program. This funding opportunity aims to support exploratory research projects that address significant gaps in current cancer research methodologies, focusing on the development and validation of novel technologies that enhance the understanding and treatment of cancer, including early detection, screening, and addressing health disparities. Eligible applicants can request up to $300,000 annually for a project period not exceeding three years, with a total of approximately $4.3 million available for 10 anticipated awards in fiscal year 2025. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects focused on the early-stage development of innovative technologies that enhance molecular and cellular analysis capabilities in cancer research, with an emphasis on technical innovation and addressing cancer health disparities. The total funding available is approximately $4.2 million, with individual grants of up to $150,000 per year for a maximum of three years. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-008.html.
    Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on developing and validating innovative technologies to enhance the quality of biospecimens used in cancer research, specifically addressing pre-analytical variations that can compromise sample integrity. The program is part of the Innovative Molecular Analysis Technologies (IMAT) initiative and seeks projects that demonstrate preliminary data supporting their feasibility, with a funding ceiling of $300,000 per year for up to three years. Applications are due by October 1, 2024, and interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-011.html.
    Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)." This initiative aims to support the development of innovative informatics tools that enhance the acquisition, analysis, dissemination, and management of cancer-related data, focusing on areas such as biology, treatment, early detection, and health disparities. The program encourages collaboration with end-users to ensure the practical utility of the proposed technologies, with approximately $2.25 million available for 5-6 awards, each with a maximum budget of $300,000 per year for up to three years. Interested applicants should note that the application process opens on May 11, 2024, with a submission deadline of November 15, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Advanced Development of Informatics Technologies for Cancer Research and Management" (RFA-CA-24-018). This initiative aims to support cooperative agreements that focus on the enhancement of emerging informatics technologies to improve data acquisition, management, analysis, and dissemination across the cancer research continuum. The program is particularly significant as it seeks to advance technologies that have shown initial viability but require further development to achieve a broader impact in cancer research, addressing critical health disparities and improving patient outcomes. NIH anticipates funding approximately four awards totaling $3.6 million for fiscal year 2025, with individual budgets capped at $600,000 per year over a five-year period. Applications are due by November 15, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)" aimed at supporting exploratory research projects that develop innovative technologies to enhance the quality of biospecimens used in cancer research. The initiative focuses on addressing pre-analytical degradation of cancer-relevant biospecimens during collection, processing, and storage, with the goal of improving sample integrity and utility for downstream analyses. This funding is particularly significant for advancing research in cancer biology, early detection, and treatment, while also addressing health disparities. Grants of up to $150,000 are available, with applications opening on March 1, 2024, and a submission deadline of October 1, 2024. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-010.html.
    Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) cooperative agreement. This funding opportunity aims to enhance the development and sustainment of informatics research resources that improve data acquisition, analysis, visualization, and interpretation across various cancer research domains, including biology, treatment, prevention, and health disparities. The initiative is crucial for maintaining and improving existing informatics tools that support cancer research, emphasizing the need for robust sustainability plans and community engagement. Approximately $1,130,000 in funding is available, with applications accepted starting May 11, 2024, and a final submission deadline of November 15, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.